SE8904239L - Ett rekombinat, humant faktor-viii-derivat - Google Patents

Ett rekombinat, humant faktor-viii-derivat

Info

Publication number
SE8904239L
SE8904239L SE8904239A SE8904239A SE8904239L SE 8904239 L SE8904239 L SE 8904239L SE 8904239 A SE8904239 A SE 8904239A SE 8904239 A SE8904239 A SE 8904239A SE 8904239 L SE8904239 L SE 8904239L
Authority
SE
Sweden
Prior art keywords
factor viii
human factor
dna segment
recombinate
derivate
Prior art date
Application number
SE8904239A
Other languages
Unknown language ( )
English (en)
Other versions
SE465222B (sv
SE8904239D0 (sv
SE465222C5 (sv
Inventor
A B Almstedt
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8904239(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to SE8904239A priority Critical patent/SE465222C5/sv
Publication of SE8904239D0 publication Critical patent/SE8904239D0/sv
Priority to NZ236276A priority patent/NZ236276A/xx
Priority to BR909007921A priority patent/BR9007921A/pt
Priority to DE69034040T priority patent/DE69034040T2/de
Priority to DK97103685T priority patent/DK0786474T3/da
Priority to DE1999175066 priority patent/DE19975066I2/de
Priority to DK91901327T priority patent/DK0506757T4/da
Priority to EP91901327A priority patent/EP0506757B2/en
Priority to HK98109933.4A priority patent/HK1009290B/en
Priority to CA002071875A priority patent/CA2071875C/en
Priority to SG9603152A priority patent/SG66753A1/en
Priority to EP97103685A priority patent/EP0786474B1/en
Priority to JP3501715A priority patent/JP2644084B2/ja
Priority to ES97103685T priority patent/ES2189897T3/es
Priority to AU70393/91A priority patent/AU645539B2/en
Priority to AT97103685T priority patent/ATE232213T1/de
Priority to AT91901327T priority patent/ATE170219T1/de
Priority to EP02009162A priority patent/EP1293513A3/en
Priority to PCT/SE1990/000809 priority patent/WO1991009122A1/en
Priority to DE69032600T priority patent/DE69032600T3/de
Priority to ES91901327T priority patent/ES2119769T5/es
Priority to IE451090A priority patent/IE904510A1/en
Priority to PT96208A priority patent/PT96208B/pt
Publication of SE8904239L publication Critical patent/SE8904239L/sv
Publication of SE465222B publication Critical patent/SE465222B/sv
Priority to NO922325A priority patent/NO309041B1/no
Priority to FI922745A priority patent/FI104260B1/sv
Priority to HU95P/P00489P priority patent/HU211504A9/hu
Publication of SE465222C5 publication Critical patent/SE465222C5/sv
Priority to HK99104067.2A priority patent/HK1019449B/en
Priority to LU90457C priority patent/LU90457I2/fr
Priority to NL990035C priority patent/NL990035I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Confectionery (AREA)
SE8904239A 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning SE465222C5 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
NZ236276A NZ236276A (en) 1989-12-15 1990-11-29 Dna encoding factor viii: comprising two polypeptide chains, a 90 kda a chain polypeptide and an 80 kda c chain polypeptide
DE69032600T DE69032600T3 (de) 1989-12-15 1990-12-06 Rekombinanter abkömmling des menschlichen faktors iii
ES91901327T ES2119769T5 (es) 1989-12-15 1990-12-06 Derivado del factor viii humano recombinante.
ES97103685T ES2189897T3 (es) 1989-12-15 1990-12-06 Un derivado del factor viii recombinante humano.
EP02009162A EP1293513A3 (en) 1989-12-15 1990-12-06 A recombinant human factor VIII derivative
DK97103685T DK0786474T3 (da) 1989-12-15 1990-12-06 Rekombinant human faktor VIII derivat
DE1999175066 DE19975066I2 (de) 1989-12-15 1990-12-06 Rekombinanter Abk¦mmling des menschlichen Faktors III.
DK91901327T DK0506757T4 (da) 1989-12-15 1990-12-06 Rekombinant human faktor VIII derivat
EP91901327A EP0506757B2 (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative
HK98109933.4A HK1009290B (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative
CA002071875A CA2071875C (en) 1989-12-15 1990-12-06 Recombinant human factor viii derivative
SG9603152A SG66753A1 (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative
EP97103685A EP0786474B1 (en) 1989-12-15 1990-12-06 A recombinant human factor VIII derivative
JP3501715A JP2644084B2 (ja) 1989-12-15 1990-12-06 組換えヒト▲ｖｉｉｉ▼因子誘導体
BR909007921A BR9007921A (pt) 1989-12-15 1990-12-06 Sequencia de dna codificando para um derivado de fator viii humano,recombinante biologicamente ativo,vetor de expressao recombinante,cellula haspedeira de origem animal,processo para a fabricacao de um derivado e derivado de fator viii humano
AU70393/91A AU645539B2 (en) 1989-12-15 1990-12-06 A recombinant human factor VIII derivative
AT97103685T ATE232213T1 (de) 1989-12-15 1990-12-06 Rekombinanter abkömmling des menschlichen faktors viii
AT91901327T ATE170219T1 (de) 1989-12-15 1990-12-06 Rekombinanter abkömmling des menschlichen faktors iii
DE69034040T DE69034040T2 (de) 1989-12-15 1990-12-06 Rekombinanter Abkömmling des menschlichen Faktors VIII
PCT/SE1990/000809 WO1991009122A1 (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative
PT96208A PT96208B (pt) 1989-12-15 1990-12-14 Processo de obtencao de uma sequencia de adn codificando um derivado recombinante do factor viii humano, de um vector e de celula recombinante e de preparacao do referido derivado.
IE451090A IE904510A1 (en) 1989-12-15 1990-12-14 A recombinant human factor viii derivative
NO922325A NO309041B1 (no) 1989-12-15 1992-06-12 DNA-sekvens, rekombinant ekspresjonsvektor og vertscelle omfattende DNA-sekvensen, samt fremgangsmÕte for fremstilling av human faktor VIII-derivat
FI922745A FI104260B1 (sv) 1989-12-15 1992-06-12 DNA som kodar för ett biologiskt aktivt rekombinanthumanfaktor VIII-derivat, rekombinant expressionsvektor och värdcell innehållande denna DNA, samt ett förfarande för framställning av ett biologisktaktivt rekombinant humanfaktor VIII-derivat
HU95P/P00489P HU211504A9 (en) 1989-12-15 1995-06-28 Recombinant human factor viii derivatives
HK99104067.2A HK1019449B (en) 1989-12-15 1998-08-14 A recombinant human factor viii derivative
LU90457C LU90457I2 (fr) 1989-12-15 1999-10-12 Refacto
NL990035C NL990035I2 (nl) 1989-12-15 1999-10-12 Een recombinante afgeleide van humane factor VIII.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

Publications (4)

Publication Number Publication Date
SE8904239D0 SE8904239D0 (sv) 1989-12-15
SE8904239L true SE8904239L (sv) 1991-06-16
SE465222B SE465222B (sv) 1991-08-12
SE465222C5 SE465222C5 (sv) 1998-02-10

Family

ID=20377785

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

Country Status (20)

Country Link
EP (3) EP1293513A3 (sv)
JP (1) JP2644084B2 (sv)
AT (2) ATE232213T1 (sv)
AU (1) AU645539B2 (sv)
BR (1) BR9007921A (sv)
CA (1) CA2071875C (sv)
DE (3) DE69032600T3 (sv)
DK (2) DK0506757T4 (sv)
ES (2) ES2119769T5 (sv)
FI (1) FI104260B1 (sv)
HU (1) HU211504A9 (sv)
IE (1) IE904510A1 (sv)
LU (1) LU90457I2 (sv)
NL (1) NL990035I2 (sv)
NO (1) NO309041B1 (sv)
NZ (1) NZ236276A (sv)
PT (1) PT96208B (sv)
SE (1) SE465222C5 (sv)
SG (1) SG66753A1 (sv)
WO (1) WO1991009122A1 (sv)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
DE69329795T2 (de) * 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE9300509D0 (sv) * 1993-02-16 1993-02-16 Kabi Pharmacia Ab Peg treatment
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
WO1997003193A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP1318198B1 (en) * 1996-05-14 2006-03-22 Biovitrum Ab Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
KR100581574B1 (ko) * 2000-03-22 2006-05-22 옥타게네 게엠베하 인간 세포주 내 재조합 혈액 응고 인자의 제조
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
PT2287288E (pt) 2002-07-09 2012-12-10 Baxter Int Meio isento de proteína animal para cultura de células
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
LT2126106T (lt) 2007-02-23 2018-01-10 Sk Chemicals Co., Ltd. Viii faktoriaus ir jo darinių gavimo ir gryninimo būdas
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
KR102170375B1 (ko) 2009-06-09 2020-10-27 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
CN102497884A (zh) 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
PL3326643T3 (pl) 2009-12-06 2021-10-25 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
EP2616486B1 (en) 2010-09-15 2019-01-02 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
DK2675902T3 (da) 2011-02-17 2019-06-03 Univ Pennsylvania Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
CN103796670A (zh) 2011-07-08 2014-05-14 比奥根艾迪克依蒙菲利亚公司 因子viii嵌合和杂合多肽及其使用方法
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
AU2012324020A1 (en) 2011-12-30 2013-07-18 Grifols, S.A. Method for purifying Factor VIII
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
EP3970737A1 (en) 2012-01-12 2022-03-23 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
RU2500818C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАР227, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 2H5 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ФАКТОРА VIII
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
SI3889173T1 (sl) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
DK2968477T3 (da) 2013-03-15 2020-03-09 Bioverativ Therapeutics Inc Faktor viii-polypeptidformuleringer
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
SG10201710616XA (en) 2013-06-28 2018-02-27 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
CN105848670A (zh) 2013-10-22 2016-08-10 Dbv技术公司 通过诱导对血液因子的耐受治疗血友病的方法
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
DK3080274T3 (da) 2013-12-09 2020-08-31 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til genom-manipulation
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
DK3193911T5 (da) * 2014-07-25 2024-10-14 Csl Behring Gmbh Forbedrede faktor VII-præparater til brug ved behandling af hæmofili A
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN115074366A (zh) 2015-04-16 2022-09-20 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
WO2017136358A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
TW202545984A (zh) 2017-08-09 2025-12-01 美商生物化學醫療公司 核酸分子及其用途
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
IL312315A (en) 2018-04-04 2024-06-01 Sigilon Therapeutics Inc Implantable particles and related methods
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US20220233650A1 (en) 2019-06-19 2022-07-28 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
JP2023537070A (ja) 2020-08-07 2023-08-30 アミカス セラピューティックス インコーポレイテッド 小胞を標的とするタンパク質及びその使用
CA3229323A1 (en) 2021-08-23 2023-03-02 Ajay MAGHODIA Optimized factor viii genes
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
JP2025534667A (ja) 2022-10-11 2025-10-17 シギロン セラピューティクス， インコーポレイテッド 疾患治療のための改変細胞及び移植可能エレメント
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) * 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
JPH0637425B2 (ja) * 1986-11-11 1994-05-18 株式会社クラレ 高沸点（メタ）アクリル酸エステルの製造方法
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JP2586092B2 (ja) * 1988-04-06 1997-02-26 三菱瓦斯化学株式会社 多官能（メタ）アクリル酸エステルの製造法
ZA909167B (en) * 1989-11-17 1993-10-15 Chiron Corp Protein complexes having Factor VIII:C activity and production thereof

Also Published As

Publication number Publication date
AU7039391A (en) 1991-07-18
FI922745A0 (fi) 1992-06-12
DE69032600T2 (de) 1999-01-07
HU211504A9 (en) 1995-11-28
EP1293513A2 (en) 2003-03-19
DE69034040T2 (de) 2003-11-20
HK1019449A1 (en) 2000-02-11
PT96208A (pt) 1991-09-30
SE465222B (sv) 1991-08-12
SE8904239D0 (sv) 1989-12-15
ES2189897T3 (es) 2003-07-16
JP2644084B2 (ja) 1997-08-25
NZ236276A (en) 1993-03-26
DK0786474T3 (da) 2003-03-03
JPH05502161A (ja) 1993-04-22
BR9007921A (pt) 1992-11-10
NL990035I1 (nl) 1999-12-01
IE904510A1 (en) 1991-07-17
EP0786474B1 (en) 2003-02-05
PT96208B (pt) 1998-05-29
CA2071875A1 (en) 1991-06-16
AU645539B2 (en) 1994-01-20
DE69034040D1 (de) 2003-03-13
CA2071875C (en) 2006-08-08
DK0506757T4 (da) 2006-02-20
EP0506757A1 (en) 1992-10-07
EP1293513A3 (en) 2003-04-02
DK0506757T3 (da) 1999-05-25
LU90457I2 (fr) 2001-04-13
NO309041B1 (no) 2000-12-04
ES2119769T3 (es) 1998-10-16
DE69032600T3 (de) 2006-07-20
EP0786474A1 (en) 1997-07-30
ES2119769T5 (es) 2006-04-16
WO1991009122A1 (en) 1991-06-27
NO922325L (no) 1992-08-11
FI104260B (sv) 1999-12-15
SG66753A1 (en) 2001-12-19
EP0506757B2 (en) 2005-10-26
DE19975066I2 (de) 2005-07-07
NO922325D0 (no) 1992-06-12
DE69032600D1 (de) 1998-10-01
HK1009290A1 (en) 1999-05-28
SE465222C5 (sv) 1998-02-10
NL990035I2 (nl) 2000-01-03
FI104260B1 (sv) 1999-12-15
ATE232213T1 (de) 2003-02-15
ATE170219T1 (de) 1998-09-15
EP0506757B1 (en) 1998-08-26

Similar Documents

Publication Publication Date Title
SE8904239L (sv) Ett rekombinat, humant faktor-viii-derivat
SE9100799D0 (sv) Recombinant human factor viii derivatives
ATE238345T1 (de) Protegrine
ATE209215T1 (de) Protegrine
DE69434083D1 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
NO971621D0 (no) Keratinocyttvekstfaktoranaloger
ATE93852T1 (de) Redox-aminsaeuren und diese enthaltende peptide.
BR9301436A (pt) Peptideo,processo para a sua preparacao,aplicacao desse peptideo e agente farmaceutico
ATE86260T1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
EA200000709A1 (ru) Бета-липотропин и его применения

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8904239-4